Neos Therapeutics Company Profile (NASDAQ:NEOS)

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics logoNeos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEOS
  • CUSIP: N/A
  • Web: www.neostx.com
Capitalization:
  • Market Cap: $244.3 million
  • Outstanding Shares: 28,081,000
Average Prices:
  • 50 Day Moving Avg: $8.88
  • 200 Day Moving Avg: $8.88
  • 52 Week Range: $4.85 - $9.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.08
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $15.62 million
  • Price / Sales: 15.64
  • Book Value: $0.93 per share
  • Price / Book: 9.35
Profitability:
  • EBIDTA: ($69,700,000.00)
  • Net Margins: -511.74%
  • Return on Equity: -611.78%
  • Return on Assets: -80.97%
Debt:
  • Debt-to-Equity Ratio: 2.33%
  • Current Ratio: 3.04%
  • Quick Ratio: 2.84%
Misc:
  • Average Volume: 1.31 million shs.
  • Beta: -0.9
  • Short Ratio: 6.71
 

Frequently Asked Questions for Neos Therapeutics (NASDAQ:NEOS)

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.83) EPS for the quarter, meeting the consensus estimate of ($0.83). The business had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. View Neos Therapeutics' Earnings History.

When will Neos Therapeutics make its next earnings announcement?

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Neos Therapeutics.

Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?

4 brokers have issued 12 month price objectives for Neos Therapeutics' stock. Their predictions range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' stock price to reach $16.75 in the next year. View Analyst Ratings for Neos Therapeutics.

What are analysts saying about Neos Therapeutics stock?

Here are some recent quotes from research analysts about Neos Therapeutics stock:

  • 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (9/12/2017)
  • 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) FDA approval of Cotempla XR-ODT in June of this year, with commercial availability in Fall of 2017, 2) On June 27, 2017, Neos announced the pricing of an underwritten public offering of $32.4MM value of common stock at a price of $6.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos." (8/9/2017)

Who are some of Neos Therapeutics' key competitors?

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the folowing people:

  • Alan Heller, Chairman of the Board
  • Vipin K. Garg Ph.D., President, Chief Executive Officer, Director
  • Richard Eisenstadt, Chief Financial Officer
  • Dorothy Engelking, Vice President of Regulatory Affairs
  • Thomas P McDonnell, Chief Commercial Officer
  • Beth P. Hecht, Director
  • Paul R. Edick, Non-Executive Director
  • Bryant E. Fong, Non-Executive Director
  • Gregory J. Robitaille, Non-Executive Director
  • John P. Schmid, Non-Executive Director

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Who owns Neos Therapeutics stock?

Neos Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (9.08%), Franklin Resources Inc. (9.65%), Vanguard Group Inc. (3.28%), Stonepine Capital Management LLC (2.07%), State Street Corp (1.16%) and Columbus Circle Investors (1.21%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell. View Institutional Ownership Trends for Neos Therapeutics.

Who sold Neos Therapeutics stock? Who is selling Neos Therapeutics stock?

Neos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including California State Teachers Retirement System and Bank of New York Mellon Corp. View Insider Buying and Selling for Neos Therapeutics.

Who bought Neos Therapeutics stock? Who is buying Neos Therapeutics stock?

Neos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Essex Investment Management Co. LLC, Russell Investments Group Ltd., Columbus Circle Investors, Vanguard Group Inc., DAFNA Capital Management LLC, State Street Corp and Virtu KCG Holdings LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell. View Insider Buying and Selling for Neos Therapeutics.

How do I buy Neos Therapeutics stock?

Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of Neos Therapeutics stock can currently be purchased for approximately $8.70.


MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  223
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neos Therapeutics (NASDAQ:NEOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.75 (92.53% upside)

Analysts' Ratings History for Neos Therapeutics (NASDAQ:NEOS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Cantor FitzgeraldSet Price TargetBuy$20.00HighView Rating Details
8/8/2017Royal Bank Of CanadaSet Price TargetOutperform$12.00MediumView Rating Details
6/20/2017BMO Capital MarketsReiterated RatingOutperform$15.00HighView Rating Details
4/5/2017Cowen and CompanyInitiated CoverageOutperform$20.00HighView Rating Details
5/18/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$33.00 -> $32.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Neos Therapeutics (NASDAQ:NEOS)
Earnings by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Earnings History by Quarter for Neos Therapeutics (NASDAQ NEOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.80)N/AView Earnings Details
8/8/2017Q2 2017($0.83)($0.83)$4.91 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.94)($0.87)$5.63 millionViewListenView Earnings Details
3/14/2017Q4 2016($1.36)($1.14)$3.50 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.64)($1.61)$1.58 millionViewN/AView Earnings Details
8/11/2016Q2($1.16)($1.65)$1.48 million$1.49 millionViewListenView Earnings Details
5/16/2016Q1($0.87)($0.79)$1.50 million$2.58 millionViewListenView Earnings Details
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
Current Year EPS Consensus Estimate: $-3.10 EPS
Next Year EPS Consensus Estimate: $-1.43 EPS

Dividends

Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neos Therapeutics (NASDAQ:NEOS)
Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 44.29%
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2016Bryant FongDirectorBuy1,500$6.54$9,810.00View SEC Filing  
8/25/2016Richard I EisenstadtCFOBuy3,710$6.82$25,302.20View SEC Filing  
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.00View SEC Filing  
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00View SEC Filing  
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.00View SEC Filing  
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.10View SEC Filing  
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.66View SEC Filing  
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neos Therapeutics (NASDAQ:NEOS)
Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
Source:
DateHeadline
finance.yahoo.com logoCorporate News Blog - Neos Therapeutics Receives FDA’s Approval for Adzenys ER(TM) Extended-Release Oral Suspension, its Third Treatment for ADHD
finance.yahoo.com - September 20 at 6:53 AM
americanbankingnews.com logoNeos Therapeutics (NEOS) versus The Competition Head to Head Analysis
www.americanbankingnews.com - September 19 at 2:30 PM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 19 at 2:38 AM
americanbankingnews.com logoFinancial Comparison: Neos Therapeutics (NEOS) vs. Its Competitors
www.americanbankingnews.com - September 17 at 4:26 AM
streetinsider.com logoNeos Therapeutics (NEOS) Granted U.S. FDA Approval of Adzenys ER (amphetamine
www.streetinsider.com - September 17 at 2:06 AM
nasdaq.com logoNeos Therapeutics to launch third medication in ADHD franchise in January 2018
www.nasdaq.com - September 16 at 6:54 AM
reuters.com logoBRIEF-Neos Therapeutics receives U.S. FDA approval
www.reuters.com - September 16 at 6:54 AM
finance.yahoo.com logoNeos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
finance.yahoo.com - September 16 at 6:53 AM
finance.yahoo.com logoNeos Therapeutics shares fall after FDA approves new formulation of ADHD drug
finance.yahoo.com - September 16 at 6:53 AM
americanbankingnews.com logoZacks: Brokerages Expect Neos Therapeutics, Inc. (NEOS) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - September 15 at 4:32 AM
nasdaq.com logoNeos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally ... - Nasdaq
www.nasdaq.com - September 7 at 6:39 AM
reuters.com logoBRIEF-Neos Therapeutics announces launch of Cotempla XR-OD extended-release orally disintegrating tablets for treatment of ADHD
www.reuters.com - September 6 at 6:45 AM
finance.yahoo.com logoNeos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
finance.yahoo.com - September 6 at 6:45 AM
globenewswire.com logoNeos Therapeutics to Participate in Three September Conferences - GlobeNewswire (press release)
globenewswire.com - August 31 at 7:42 AM
finance.yahoo.com logoNeos Therapeutics to Participate in Three September Conferences
finance.yahoo.com - August 31 at 7:42 AM
prnewswire.com logoOrally Disintegrating Tablets Market to Reach US$ 27 Bn by 2025 - Persistence Market Research
www.prnewswire.com - August 29 at 5:16 AM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - August 27 at 2:24 PM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 25 at 2:38 AM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - August 23 at 6:14 AM
americanbankingnews.com logoValuEngine Upgrades Neos Therapeutics, Inc. (NASDAQ:NEOS) to Sell
www.americanbankingnews.com - August 12 at 7:34 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Neos Therapeutics, Inc. (NEOS) a $20.00 Price Target
www.americanbankingnews.com - August 9 at 11:38 PM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Issues Earnings Results
www.americanbankingnews.com - August 9 at 5:54 PM
reuters.com logoBRIEF-Neos Therapeutics Q2 loss per share $0.83
www.reuters.com - August 9 at 3:01 AM
finance.yahoo.com logoInvestor Network: Neos Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 3:01 AM
finance.yahoo.com logoNeos Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 3:01 AM
finance.yahoo.com logoNeos Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 3:01 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Neos Therapeutics, Inc.'s FY2017 Earnings (NEOS)
www.americanbankingnews.com - August 3 at 9:50 AM
feeds.benzinga.com logoNeos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017
feeds.benzinga.com - August 2 at 8:21 AM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 31 at 6:46 PM
americanbankingnews.com logoCantor Fitzgerald Initiates Coverage on Neos Therapeutics, Inc. (NASDAQ:NEOS)
www.americanbankingnews.com - July 31 at 5:31 PM
americanbankingnews.com logoNeos Therapeutics, Inc. (NASDAQ:NEOS) Expected to Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - July 20 at 12:24 AM
seekingalpha.com logoNeos Looks Attractive With Short And Long Term Catalysts
seekingalpha.com - July 1 at 3:36 AM
benzinga.com logoAttention To Details: Neos' ADHD Portfolio
www.benzinga.com - June 27 at 6:53 PM
reuters.com logoBRIEF-Neos Therapeutics announces proposed offering of common stock
www.reuters.com - June 27 at 6:53 PM
streetinsider.com logoForm 8-K Neos Therapeutics, Inc. For: Jun 26
www.streetinsider.com - June 27 at 6:53 PM
finance.yahoo.com logoNeos Therapeutics Announces Pricing of Underwritten Public Offering of $32.4 Million of Common Stock
finance.yahoo.com - June 27 at 6:53 PM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - June 23 at 10:24 PM
bizjournals.com logoNeos nets second ADHD drug approval - for no-swallow, dissolve pill
www.bizjournals.com - June 23 at 7:19 PM
finance.yahoo.com logoShire wins U.S. approval for long-acting ADHD drug
finance.yahoo.com - June 21 at 5:56 AM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - June 20 at 11:40 PM
247wallst.com logoNeos Therapeutics Slides Despite FDA Approval
247wallst.com - June 20 at 7:53 PM
finance.yahoo.com logoShire's long-acting ADHD drug wins U.S. approval
finance.yahoo.com - June 20 at 7:53 PM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Receives Outperform Rating from BMO Capital Markets
www.americanbankingnews.com - June 20 at 12:28 PM
nasdaq.com logoNeos Therapeutics Says ADHD Drug Cotempla XR-ODT Gets FDA Approval
www.nasdaq.com - June 20 at 7:45 AM
finance.yahoo.com logoNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
finance.yahoo.com - June 19 at 10:53 PM
finance.yahoo.com logoNeos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference
finance.yahoo.com - June 14 at 9:25 AM
americanbankingnews.com logoNeos Therapeutics, Inc. (NEOS) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 13 at 4:40 PM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 10 at 7:26 AM
reuters.com logoBRIEF-Neos Therapeutics enters into first amendment to its existing facility agreement with lenders
www.reuters.com - June 5 at 7:27 PM
americanbankingnews.com logoZacks Investment Research Upgrades Neos Therapeutics Inc (NEOS) to Buy
www.americanbankingnews.com - June 3 at 7:12 AM

Social

Chart

Neos Therapeutics (NEOS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff